The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for guselkumab (Tremfya) on September 19, 2025. This action by the FDA indicates an expansion of the drug's approved uses, based on new data demonstrating its efficacy.
What this means
This supplemental approval for guselkumab signifies that the FDA has reviewed and accepted new data supporting the drug's efficacy for an expanded or modified indication. While the specific details of the new indication are not provided in this update, such approvals typically allow healthcare providers to prescribe the medication for a broader patient population or a different set of clinical circumstances where its efficacy has been demonstrated.
Source
The information regarding this supplemental approval for guselkumab was obtained from the U.S. Food and Drug Administration (FDA) website. The approval, identified as BLA 761061 S-26, was posted on September 19, 2025, on accessdata.fda.gov.